Trials / Recruiting
RecruitingNCT06382987
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | According to the product label |
| DRUG | Apremilast | According to the product label |
Timeline
- Start date
- 2024-01-22
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
- First posted
- 2024-04-25
- Last updated
- 2024-04-25
Locations
2 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06382987. Inclusion in this directory is not an endorsement.